Theravance Biopharma, Inc.
Theravance Biopharma discovers, develops, and commercializes respiratory medicines in the US and Europe. They offer YUPELRI for COPD treatment and Ampreloxetine, an investigational drug for neurogenic orthostatic hypotension. They also have TRELEGY for COPD and asthma treatment. The company has agreements with Pfizer and Viatris.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |